Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease.

Objective: 6-Thioguanine has been used as an alternative immunomodulator in the treatment of inflammatory bowel disease but data on its efficacy and safety are limited. The aim of this study was to analyse our experience of the efficacy and safety of 6-thioguanine in inflammatory bowel disease.

Material And Methods: Patients attending the inflammatory bowel disease clinic who were started on 6-thioguanine therapy were included in this prospective observational study.

Is coeliac disease a potentially treatable cause of liver failure?

Hypertransaminasaemia is a common abnormality found in up to 40% of untreated coeliac patients, which resolves with the institution of a gluten-free diet. A much rarer occurrence is the association of chronic liver disease with coeliac disease. Primary biliary cirrhosis, primary sclerosing cholangitis, and chronic autoimmune hepatitis have all been recognized in coeliac patients.

Effectiveness of antiinfectives.

Background: Helicobacter pylori is one of the most common infections of mankind, with persistent colonization causing significant morbidity and mortality.

Treatment: First-line therapy, consisting of 7-day treatment with a proton pump inhibitor or ranitidine bismuth citrate, amoxicillin and clarithromycin, with second-line therapy, consisting of a proton pump inhibitor, bismuth, metronidazole, and tetracycline, in the case of failure, is chosen as the most cost-effective method of H. pylori eradication.

Eradication of Helicobacter pylori: recent advances in treatment.

Helicobacter pylori plays a key role in dyspepsia, peptic ulcer disease, and gastric neoplasia and eradication of the infection has become an important treatment goal in clinical practice. Seven-day proton-pump inhibitor-amoxicillin-clarithromycin triple therapy is the current first-line therapy for H. pylori but eradication rates are compromised by poor compliance and antibiotic resistance.

Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients.

Background: Optimal management approach is not well defined for subjects who fail initial first- and second-line Helicobacter pylori eradication attempts and are dealt on a case-by-case basis by the specialists.

Aim: To evaluate the efficacy and safety of standard and 'rescue' eradication therapies at primary and secondary care levels.

Methods: H.

Therapy of Helicobacter pylori.

This represents an overview of the main data published over the last year on the therapy of Helicobacter pylori. The problem of increasing failure of H. pylori eradication has been the main focus, with increasing resistance and poor patient compliance being the main culprits.